Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Assessment of The Effect of Tocilizumab in Adult Hospitalized COVID-19 Pneumonia Patients: A Clinical Trial

View through CrossRef
ackground: Coronavirus disease 2019 (COVID-19) is a life-threatening infectious disease causing potentially severe acute respiratory infection which may lead to multi-organ dysfunction or failure due to severe acute respiratory syndrome coronavirus (SARS-CoV-2) also known as novel coronavirus (nCoV). Tocilizumab is anti-interleukin-6 receptor antibody may have potential role in minimizing mortality and mechanical ventilation requirements among hospitalized COVID-19 patients. Objective: To analyze the effect of tocilizumab in adult hospitalized COVID-19 pneumonia patients. Methods: This non-randomized, controlled, open-label trial was carried out at a tertiary care hospital, Sylhet, Bangladesh. Hospitalized COVID-19 pneumonia patients with hypoxia ( oxygen saturation < 92% on air or required oxygen) and proof of systemic inflammation(C-reactive protein ≥50mg/L) were assigned (in 1:1 ratio) to receive a standard care plus single dose of tocilizumab (8mg/kg up to a maximum of 800mg) or only standard care, who were not provided mechanical ventilation. Primary outcomes were 28-day mortality and necessity of mechanical ventilation. Results: The mean age was 59.08±12.39 years in tocilizumab group and mean age was 55.41±12.82 years in control group. Maximum patients were >60 years. The most common symptoms were fever (44.4%) then cough (38.9%), and others including diarrhoea, fatigue (33.3%). Majority risk factors were DM (47.7%) followed by HTN (30.5%). Mortality was more in control group than tocilizumab group which was 83.3% and 44.4% respectively. It is also observed that tocilizumab group patients needed mechanical ventilation significantly lower than the control group which was 19.4% and 44.4% respectively. The difference was statistically remarkable between the two groups (P<0.05). Conclusion: This study shows that hospitalized COVID-19 patients who were not receiving mechanical ventilation,tocilizumab increased survival rate and reduced the need of mechanical ventilation.
Title: Assessment of The Effect of Tocilizumab in Adult Hospitalized COVID-19 Pneumonia Patients: A Clinical Trial
Description:
ackground: Coronavirus disease 2019 (COVID-19) is a life-threatening infectious disease causing potentially severe acute respiratory infection which may lead to multi-organ dysfunction or failure due to severe acute respiratory syndrome coronavirus (SARS-CoV-2) also known as novel coronavirus (nCoV).
Tocilizumab is anti-interleukin-6 receptor antibody may have potential role in minimizing mortality and mechanical ventilation requirements among hospitalized COVID-19 patients.
Objective: To analyze the effect of tocilizumab in adult hospitalized COVID-19 pneumonia patients.
Methods: This non-randomized, controlled, open-label trial was carried out at a tertiary care hospital, Sylhet, Bangladesh.
Hospitalized COVID-19 pneumonia patients with hypoxia ( oxygen saturation < 92% on air or required oxygen) and proof of systemic inflammation(C-reactive protein ≥50mg/L) were assigned (in 1:1 ratio) to receive a standard care plus single dose of tocilizumab (8mg/kg up to a maximum of 800mg) or only standard care, who were not provided mechanical ventilation.
Primary outcomes were 28-day mortality and necessity of mechanical ventilation.
Results: The mean age was 59.
08±12.
39 years in tocilizumab group and mean age was 55.
41±12.
82 years in control group.
Maximum patients were >60 years.
The most common symptoms were fever (44.
4%) then cough (38.
9%), and others including diarrhoea, fatigue (33.
3%).
Majority risk factors were DM (47.
7%) followed by HTN (30.
5%).
Mortality was more in control group than tocilizumab group which was 83.
3% and 44.
4% respectively.
It is also observed that tocilizumab group patients needed mechanical ventilation significantly lower than the control group which was 19.
4% and 44.
4% respectively.
The difference was statistically remarkable between the two groups (P<0.
05).
Conclusion: This study shows that hospitalized COVID-19 patients who were not receiving mechanical ventilation,tocilizumab increased survival rate and reduced the need of mechanical ventilation.

Related Results

KECEMASAN SAAT PANDEMI COVID 19: LITERATUR REVIEW Hardiyati, Efri Widianti, Taty Hernawaty Departemen Keperawatan Jiwa Poltekkes Kemenkes Mamuju Sulbar, Universitas Pad...
The effectiveness of Tocilizumab in severe covid 19 pneumonia among critically ill patients
The effectiveness of Tocilizumab in severe covid 19 pneumonia among critically ill patients
Background: Tocilizumab, an interleukin-6 (IL-6) antagonist, is being evaluated for the management of covid-19 pneumonia. The objective of this study was to assess the effectivenes...
Tocilizumab May Be a Key in Therapy for Cytokine Release Syndrome in Older Patients With Severe Symptoms of COVID-19
Tocilizumab May Be a Key in Therapy for Cytokine Release Syndrome in Older Patients With Severe Symptoms of COVID-19
Abstract Background Older adults are more susceptible to the novel coronavirus disease 2019 (hereafter, COVID-19) and more likely to develop severe illness. Cytokine releas...
Evaluating the Role of Tocilizumab on Mortality Rate Among Severe and Critically Ill COVID-19 Patients in the Gaza Strip
Evaluating the Role of Tocilizumab on Mortality Rate Among Severe and Critically Ill COVID-19 Patients in the Gaza Strip
Background: Coronavirus disease 2019 (COVID-19) has spread worldwide and poses a serious public health-threat. High IL-6 levels were associated with the severity of COVID-19 and de...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...

Back to Top